HCM · HUTCHMED (China) Ltd
$12.20
+0.04 (+0.33%)
At close · Aug 14
Market Cap
$2.12B
Shares
173.81M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$548.51M
-13%
FY2025
Net Income
$456.91M
+1111%
FY2025
Gross Margin
38.68%
-6pp
FY2025
Operating Margin
-7.14%
-0.2pp
FY2025
Diluted EPS
$0.52
+1200%
FY2025
Operating Cash Flow
-$64.66M
-13109.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $548.51M | $630.2M | $838M | $426.41M | $356.13M | $227.98M | $204.89M | $214.11M | $241.2M | $216.08M | $178.2M | $87.33M | |
| $336.35M | $348.88M | $384.45M | $311.1M | — | — | — | — | $169.76M | $149.13M | $104.86M | $53.48M | |
| $212.16M | $281.32M | $453.55M | $115.31M | — | — | — | — | $71.44M | $66.95M | $73.34M | $33.85M | |
| 38.68% | 44.64% | 54.12% | 27.04% | — | — | — | — | 29.62% | 30.98% | 41.16% | 38.76% | |
| $148.3M | $212.11M | $302M | $386.89M | $299.09M | $174.78M | $138.19M | $114.16M | $75.52M | $66.87M | $47.37M | $29.91M | |
| $66.72M | $64.3M | $79.78M | $92.17M | $89.3M | $50.02M | $39.21M | $30.91M | $23.96M | $21.58M | $19.62M | $12.71M | |
| $13.31M | $12.34M | $8.21M | $8.66M | $7.19M | $6.06M | $4.94M | $3.59M | $2.58M | $2.34M | $2.02M | $1.27M | |
| — | — | — | — | — | — | — | — | — | $262.78M | $187.97M | $105.59M | |
| $587.67M | $673.91M | $819.62M | $834.1M | $684.45M | $424.64M | $351.28M | $306.75M | $294.62M | $262.78M | $187.97M | — | |
| -$39.16M | -$43.71M | $18.38M | -$407.69M | -$328.32M | -$196.67M | -$146.39M | -$92.64M | -$53.42M | -$46.7M | -$9.77M | -$18.26M | |
| -7.14% | -6.94% | 2.19% | -95.61% | -92.19% | -86.27% | -71.45% | -43.27% | -22.15% | -21.61% | -5.48% | -20.91% | |
| -$25.85M | -$31.36M | $26.58M | -$399.03M | -$321.13M | -$190.61M | -$141.44M | -$89.05M | -$50.84M | -$44.36M | -$7.76M | -$16.99M | |
| $2.87M | $2.87M | $759K | $652K | $592K | $787K | $1.03M | $1.01M | $1.46M | $1.63M | $1.4M | $1.52M | |
| $49.88M | $40.08M | $36.15M | $9.6M | $2.08M | $3.24M | $4.94M | $5.98M | $1.22M | $502K | $451K | $559K | |
| $60.96M | $42.6M | $39.93M | -$2.73M | -$8.73M | $6.93M | $5.28M | $5.99M | -$119K | -$659K | -$769K | -$1.7M | |
| $22.65M | $46.47M | $47.3M | $49.75M | $60.62M | $79.05M | $40.7M | $19.33M | $33.65M | $66.24M | $22.57M | $15.18M | |
| $498.69M | -$1.11M | $58.31M | -$410.42M | -$215.74M | -$189.73M | -$141.11M | -$86.66M | -$53.54M | $20.52M | $13.44M | -$3.26M | |
| $63.61M | $7.19M | $4.51M | -$283K | $11.92M | $4.83M | $3.27M | $3.96M | $3.08M | $4.33M | $1.61M | $1.34M | |
| $456.91M | $37.73M | $100.78M | -$360.84M | -$194.65M | -$125.73M | -$106.02M | -$74.81M | -$26.74M | $11.7M | $7.99M | -$7.31M | |
| 83.3% | 5.99% | 12.03% | -84.62% | -54.66% | -55.15% | -51.75% | -34.94% | -11.08% | 5.41% | 4.49% | -8.37% | |
| $823K | $441K | $314K | $449K | $27.61M | $10.21M | $2.35M | $3.52M | $3.77M | $2.86M | $2.43M | $3.22M | |
| — | — | — | — | — | — | — | — | -$26.74M | $11.7M | -$35.01M | -$32.82M | |
| $458.85M | $34.31M | $94.54M | -$368.31M | -$192.11M | -$117.4M | -$109.63M | -$80.48M | -$17.03M | $2.41M | $3.14M | -$9.74M | |
| USD/shares | $0.53 | $0.04 | $0.12 | -$0.43 | -$0.25 | -$0.18 | -$0.16 | -$0.11 | -$0.04 | $0.20 | -$0.64 | -$0.62 |
| USD/shares | $0.52 | $0.04 | $0.12 | -$0.43 | -$0.25 | -$0.18 | -$0.16 | -$1.13 | -$0.43 | $0.20 | -$0.64 | -$0.62 |
| shares | 858.28M | 855.35M | 849.65M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 59.72M | 54.66M | 52.56M |
| shares | 872.89M | 872.83M | 869.2M | 847.14M | 792.68M | 697.93M | 665.68M | 66.43M | 61.72M | 59.97M | 54.66M | 52.56M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2024: $142.99M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.11×
EV/EBIT
—
Peer median 16.59×
P/E (TTM)
—
Peer median 15.60×
Peer medians compare against the 46 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Oncology or Immunology Segment | $285,539,000 | $363,365,000 | $528,616,000 | $163,844,000 | $119,610,000 | $30,215,000 | — | — |
| Other Ventures Segment | $262,973,000 | $266,836,000 | $309,383,000 | $262,565,000 | $236,518,000 | $197,761,000 | — | — |
| Commercial Platform | — | — | — | — | — | — | $188,864,000 | $176,461,000 |
| Innovation Platform | — | — | — | — | — | — | $16,026,000 | $37,648,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| China | $407,454,000 | $452,413,000 | $484,895,000 | $426,409,000 | $236,518,000 | $197,761,000 | $178,098,000 | $172,876,000 |
| United States and Others | $141,058,000 | $177,788,000 | $353,104,000 | — | — | — | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Goods Distribution | $262,973,000 | $266,836,000 | $309,383,000 | $262,565,000 | $236,518,000 | $197,761,000 | $175,514,000 | $161,216,000 |
| Marketed Products | $100,637,000 | $128,008,000 | $83,087,000 | $57,057,000 | $33,937,000 | $11,329,000 | $8,113,000 | $3,324,000 |
| Other Collaboration Royalties Revenue | $68,419,000 | $71,041,000 | $32,470,000 | $26,310,000 | $15,064,000 | $4,890,000 | $2,653,000 | $261,000 |
| Commercialization Services | $45,300,000 | $52,485,000 | $48,608,000 | $41,275,000 | $27,428,000 | $3,734,000 | $2,584,000 | $11,660,000 |
| License and Collaborations Manufacturing Supply | $31,189,000 | $10,392,000 | $4,718,000 | — | — | — | — | — |
| Collaboration Research and Development | $27,904,000 | $57,968,000 | $80,397,000 | $23,741,000 | $18,995,000 | $9,771,000 | $15,532,000 | $17,681,000 |
| Other Collaboration Licensing Revenue | $12,090,000 | $43,000,000 | $278,855,000 | $14,954,000 | $23,661,000 | — | — | $12,135,000 |
| Research and Development Services | — | $471,000 | $481,000 | $507,000 | $525,000 | $491,000 | $494,000 | $7,832,000 |
Key facts
CIK
1648257
CUSIP
44842L103
13F (30d)
55 filings
55 filers
Visit website
Investor relations